| Literature DB >> 28281242 |
Vaithinathan Selvaraju1, Sumanth C Suresh1, Mahesh Thirunavukkarasu1, Jayakanthan Mannu2, Jocelyn L C Foye3, Premendu P Mathur2,4, J Alexander Palesty5, Juan A Sanchez1, David W McFadden6, Nilanjana Maulik7.
Abstract
We examined the effects of overexpressing HSPA12B on angiogenesis and myocardial function by intramyocardial administration of adenovirus encoding HSPA12B (Ad. HSPA12B) in a streptozotocin-induced diabetic rat subjected to myocardial infarction. Rats were divided randomly into six groups: control sham (CS) + Ad.LacZ, control myocardial infarction (CMI) + Ad.LacZ, control MI + Ad.HSPA12B, diabetic sham (DS) + Ad.LacZ, diabetic MI + Ad.LacZ and diabetic MI + Ad.HSPA12B. Following MI or sham surgery, the respective groups received either Ad.LacZ or Ad.HSPA12B via intramyocardial injections. We observed increased capillary and arteriolar density along with reduced fibrosis and preserved heart functions in DMI-AdHSPA12B compared to DMI-AdLacZ group. Western blot analysis demonstrated enhanced HSPA12B, vascular endothelial growth factor (VEGF), thioredoxin-1 (Trx-1) expression along with decreased expression of thioredoxin interacting protein (TXNIP) and A kinase anchoring protein 12 (AKAP12) in the DMI-AdHSPA12B compared to DMI-AdLacZ group. Our findings reveal that HSPA12B overexpression interacts with AKAP12 and downregulate TXNIP in diabetic rats following acute MI.Entities:
Keywords: AKAP12; All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.; Cardiovascular disease; Communicated by: Associate Editor Lorrie Kirshenbaum oversaw the review of this article.; Gene therapy; Myocardial infarction; VEGF; Vaithinathan Selvaraju and Sumanth C Suresh both contributed equally
Mesh：
Substances：
Year: 2017 PMID： 28281242 DOI： 10.1007/s12265-017-9734-4
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN： 1937-5387 Impact factor: 4.132